Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Metabolic Technologies, LLC manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These actions are distributed among 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's current prosecution is shared across multiple technical and administrative channels within the patent office.
CHONG, YONG SOO is the busiest examiner for the company, currently overseeing 2 pending office actions. For the practitioner, this means that a majority of the 3 pending office actions are subject to the specific examination style of CHONG, YONG SOO. Because 2 pending office actions are assigned to this individual, the company's prosecution strategy is heavily influenced by this examiner's review.
The involvement of 2 distinct art units suggests that the subject matter of the 3 pending office actions spans different technical niches within the Biotechnology & Pharmaceuticals technology area. This diversity requires the company to manage different sets of examiner preferences and art unit standards. The current data reflects a distributed approach to patent acquisition, with the workload split between the 2 distinct examiners identified.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 2 | 43.8% | +41.8% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17076493 | METHOD OF ADMINISTERING BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) | CHONG, YONG SOO | 22d overdue |
| 16240211 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) ASSOSIATED WITH INTERMITTENT FASTING | CHONG, YONG SOO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17076493 | METHOD OF ADMINISTERING BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) | CHONG, YONG SOO | 22d overdue |
| 16952673 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR JOINT STABILITY | PUTTLITZ, KARL J | 10d overdue |
| 16240211 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) ASSOSIATED WITH INTERMITTENT FASTING | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16952673 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR JOINT STABILITY | PUTTLITZ, KARL J | 1646 | §103 | Non-Final OA | 10d overdue | Pending | Nov 19, 2020 |
| 17076493 | METHOD OF ADMINISTERING BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) | CHONG, YONG SOO | 1623 | §102§103 | Final Rejection | 22d overdue | Pending | Oct 21, 2020 |
| 16240211 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) ASSOSIATED WITH INTERMITTENT FASTING | CHONG, YONG SOO | 1623 | §103§112 | Final Rejection | — | Pending | Jan 04, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMetabolic Technologies, LLC has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Yong Soo Chong has the most, with 2 of Metabolic Technologies, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
